Pharmacodynamics of progesterone women, this effect being the result of suppression of the mid-cycle surge in gonadotropin secretion, is 300 mg/day. However, this figure is based on limited clinical data. Conversely, treatment with a high dosage of oral progesterone of 100 mg four times per day (or 400 mg/day total) in men for 10 days that resulted in approximately mid-luteal phase levels of progesterone (7.9–9.4 ng/mL; measured by ) did not cause any change in testosterone levels, suggesting that progesterone has little or no antigonadotropic effect in males at typical clinical dosages. In addition, a study found that administration of 1,000 mg/day oral
Centre for Menstrual Cycle and Ovulation Research stated that its research shows overall that regular menstrual cycles with ovulation help prevent osteoporosis, breast cancer, and heart disease. Dr. Prior has called menstrual cycles "a vital sign". CeMCOR does not conduct research funded by the pharmaceutical industry. Centre for Menstrual Cycle and Ovulation Research The Centre for Menstrual Cycle and Ovulation Research (CeMCOR) is a health research centre in Vancouver. According to the University of British Columbia, CeMCOR is the only centre in the world that focuses on ovulation and the causes and consequences of ovulation disturbances. CeMCOR is known for research on progesterone-only therapy for menopausal hot